<DOC>
	<DOCNO>NCT00384969</DOCNO>
	<brief_summary>The objective phase I part study determine maximum tolerate dose dose limit toxicity combination RAD001 sorafenib patient untreated metastatic kidney cancer .</brief_summary>
	<brief_title>Sorafenib RAD001 Renal Cell Carcinoma</brief_title>
	<detailed_description>Phase I study open-label dose escalation study determine MTD combination sorafenib RAD001 . There 7-day sorafenib run-in period prior start RAD001 cycle 1 determine pharmacokinetic effect add RAD001 sorafenib drug level . Starting dos set RAD001 2.5 mg PO QD sorafenib 400mg PO BID , continuously . Cycle length 4 week . Between 3 18 patient treated phase I portion study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Histologically cytologicallyconfirmed renal cell carcinoma contain predominant ( &gt; 50 % ) clear cell histology , metastatic unresectable 2 . Cytoreductive nephrectomy allow 3 . Evidence RECISTdefined measurable disease ( lesion accurately measure least one dimension long diameter ≥ 20mm use conventional technique ≥10 mm spiral CT scan ) 4 . Male female least 21 year old 5 . ECOG performance status 01 6 . Adequate bone marrow function : 1 . ANC ≥ 1500/uL 2. platelet count ≥ 100,000/uL 3. hemoglobin ≥ 9.0 g/dL 7 . Adequate hepatic function : 1 . Total bilirubin ≤ 1.5 X ULN 2 . AST ( SGOT ) ≤ 2.5 X ULN 3 . ALT ( SGPT ) ≤ 2.5 X ULN 8 . Adequate renal function determine either : 1 . Calculated measured creatinine clearance ≥ 40 mL/min ( calculated creatinine clearance , CockroftGault equation use ) Modified CockcroftGault formula : ( ( 140 age ( yr ) ) x ( actual weight ( kg ) ) ) / ( 72 x serum creatinine ( mg/dl ) ) * Multiply another factor 0.85 female 2 . Serum creatinine ≤ 1.5 X ULN 9 . Able swallow oral medication 10 . Resolution preexist toxicity prior therapy NCI CTCAE V3.0 ≤ grade 1 11 . Signed date informed consent document 12 . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure 13 . More 28 day since prior therapy , include investigational agent surgical procedure 1 . Collecting duct , papillary , chromophobe type renal cell carcinoma without clear cell component exclude . Transitional cell carcinoma renal pelvis exclude 2 . No two prior systemic regimen renal cell carcinoma 3 . Phase I : No prior treatment sorafenib . Phase II : No prior treatment prior antiVEGF therapy , include sorafenib , sunitinib , thalidomide , bevacizumab 4 . No prior treatment RAD001 , CCI779 , similar agent 5 . Prior surgery , radiation therapy , systemic therapy renal cell carcinoma within 4 week start study treatment 6 . History known brain metastasis , spinal cord compression , carcinomatous meningitis , new evidence brain leptomeningeal disease screen CT MRI scan 7 . Any follow within 12 month prior study drug administration : myocardial infarction , unstable severe angina , coronary peripheral artery bypass graft , NYHA functional Class II , III , IV congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism 8 . Hypertension unable control medication 9 . Known human immunodeficiency virus ( HIV ) acquire immune deficiency syndrome ( AIDS ) relate illness 10 . `` Currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider less 30 % risk relapse 11 . Current treatment another clinical trial 12 . Pregnant breastfeed 13 . Chronic treatment systemic steroid immunosuppressive agent 14 . Patients active bleed diathesis oral vitamin K antagonist medication ( except low dose warfarin ) 15 . History malabsorption syndrome , disease significantly affect gastrointestinal function major resection stomach small bowel could interfere absorption , distribution , metabolism , excretion study drug 16 . Any serious and/or unstable preexist medical , psychiatric , condition ( include lab abnormality ) could interfere subject safety obtain informed consent . Examples include uncontrolled diabetes , nonhealing wound , severe infection , severe malnutrition , ventricular arrhythmia , active ischemic heart disease , chronic liver renal disease , active upper GI tract ulceration</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>RAD001</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Metastatic</keyword>
</DOC>